BioCryst Pharmaceuticals, Inc. (BCRX)
7.51
-0.17
(-2.21%)
USD |
NASDAQ |
Nov 13, 10:06
BioCryst Pharmaceuticals Free Cash Flow (Quarterly) : 32.46M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 32.46M |
| June 30, 2026 | 103.77M |
| March 31, 2026 | -62.54M |
| December 31, 2025 | 275.23M |
| September 30, 2025 | 39.77M |
| June 30, 2025 | 40.59M |
| March 31, 2025 | -28.18M |
| December 31, 2024 | -4.54M |
| September 30, 2024 | 7.63M |
| June 30, 2024 | -1.925M |
| March 31, 2024 | -54.31M |
| December 31, 2023 | -9.472M |
| September 30, 2023 | -20.88M |
| June 30, 2023 | -19.28M |
| March 31, 2023 | -47.67M |
| December 31, 2022 | -24.38M |
| September 30, 2022 | -32.62M |
| June 30, 2022 | -28.00M |
| March 31, 2022 | -78.21M |
| December 31, 2021 | -33.57M |
| September 30, 2021 | -23.64M |
| June 30, 2021 | -26.22M |
| March 31, 2021 | -61.11M |
| December 31, 2020 | -44.79M |
| September 30, 2020 | -38.43M |
| Date | Value |
|---|---|
| June 30, 2020 | -31.11M |
| March 31, 2020 | -23.40M |
| December 31, 2019 | -10.53M |
| September 30, 2019 | -27.72M |
| June 30, 2019 | -24.59M |
| March 31, 2019 | -27.09M |
| December 31, 2018 | -24.09M |
| September 30, 2018 | -35.07M |
| June 30, 2018 | -14.08M |
| March 31, 2018 | -19.69M |
| December 31, 2017 | -10.63M |
| September 30, 2017 | -12.62M |
| June 30, 2017 | -9.688M |
| March 31, 2017 | -8.53M |
| December 31, 2016 | -5.853M |
| September 30, 2016 | -17.74M |
| June 30, 2016 | -13.02M |
| March 31, 2016 | -22.10M |
| December 31, 2015 | -18.87M |
| September 30, 2015 | -12.80M |
| June 30, 2015 | 17.73M |
| March 31, 2015 | -4.291M |
| December 31, 2014 | -13.96M |
| September 30, 2014 | -8.634M |
| June 30, 2014 | -7.102M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Amgen, Inc. | 3.654B |
| Halozyme Therapeutics, Inc. | 255.22M |
| Neurocrine Biosciences, Inc. | 375.40M |
| Agenus, Inc. | -20.10M |
| Anika Therapeutics, Inc. | 6.716M |